Fig. 5

Inhibitor or knockout of NLRP3 decreased NLRP3-related inflammation, CSF secretion and hydrocephalus. A, B Representative T2-weighted images of brain tissue, 3D reconstruction of the lateral ventricle after different NLRP3 treatments (A) and lateral ventricle volumes (B) measured via T2-weighted images (6 rats/group, one-way ANOVA). C CSF secretion rate in the MCC950-inhibited NLRP3 and Nlrp3^−/− groups (6–8 rats/group, one-way ANOVA). D Representative images of immunofluorescence staining for NLRP3 expression in the choroid plexus 3 days after ICH-IVH and different treatments. Bar = 50 μm. E–H Western blot analysis of NLRP3, caspase-1, and IL-1β in the choroid plexus of ICH-IVH rats, MCC950-treated rats and MSU-treated rats on day 3 (n = 5, 6 rats/sample, one-way ANOVA). I Western blot analysis of NLRP3, caspase-1, and IL-1β in the choroid plexus after ICH-IVH in the control and Nlrp3^−/− groups (n = 5, 6 rats/sample, Welch’s two-tailed unpaired t-test). J mNSS (6 rats/group, one-way ANOVA). K Number of hindlimb drops recorded for a walking task in which the rat walks over a rotating beam toward the home cage on a platform (6 rats/group, one-way ANOVA). L Testing for front grip strength at different time points (6 rats/group, one-way ANOVA). B, C, F–H, J–L ICH-IVH indicates ICH-IVH (WT) + saline; MCC950 indicates ICH-IVH (WT) + MCC950; MSU indicates ICH-IVH (WT) + MCC950 + MSU; Nlrp3^−/− indicates ICH-IVH (Nlrp3^−/−). The values are expressed as the means ± SDs; **p < 0.01 and *p < 0.05